Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Axitinib in Anti-PD1 Refractory Advanced Melanoma
NCT04493203Phase 2Completed
- Start
- Dec 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib in melanoma. Started Dec 2020; status: completed.
02
Drugs
axitinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04493203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493203.